Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1

Interventions

pembrolizumab 19Paclitaxel 10Carboplatin 10Magnetic Resonance Spectroscopy 9Docetaxel 9Cyclophosphamide 9Specimen Handling 8Cisplatin 8Gemcitabine 7Drug Therapy 7sargramostim 6Pemetrexed 6Nivolumab 6fludarabine 5aldesleukin 5Trastuzumab 5Bevacizumab 5Taxes 4Fluorouracil 4Blood Specimen Collection 4Amifostine 4veliparib 3pegfilgrastim 3Topotecan 3Irinotecan 3IFL protocol 3Fluorodeoxyglucose F18 3Etoposide 3Early Intervention, Educational 3tariquidar 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × Automobiles × Gynecologic × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡